Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome

IMPORTANCE: Treatment options for Sézary syndrome (SS) are limited and associated with low response rates. Brentuximab vedotin is a CD30-directed antibody-drug conjugate approved for refractory CD30-positive cutaneous T-cell lymphoma. However, limited data exist on its efficacy in SS, including in t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA Dermatol
Asıl Yazarlar: Lewis, Daniel J., Haun, Paul L., Samimi, Sara S., Vittorio, Carmela C., Villasenor-Park, Jennifer, Barta, Stefan K., Landsburg, Daniel J., Svoboda, Jakub, Nasta, Sunita D., Schuster, Stephen J., Rook, Alain H., Kim, Ellen J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Medical Association 2020
Konular:
Brief Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7774044/
https://ncbi.nlm.nih.gov/pubmed/33377934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2020.4901
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller